Haymarket takes over oncology titles

Share this article:

Haymarket Medical has taken over the operations of two US HealthCare Communications oncology titles—The American Journal of Hematology/Oncology and Oncology Nursing News.

Haymarket Medical's parent company owns MM&M. Terms of the deal were not disclosed.

Haymarket brought on two execs from Quadrant HealthCom to run it. Steven Svec, who was VP/group publisher at Quadrant, will serve as publisher of the titles, and Chad Holloway, an associate publisher at Quadrant, will serve as sales director.

The American Journal of Hematology/Oncology remains a monthly, with a circulation of around 40,000 oncologists, hematology-oncologists and sub-specialists, and will continue to be based in San Diego. Oncology Nursing News will go down to a bimonthly schedule, with a circulation of around 29,000, and will be moved into Haymarket's New York offices.

Haymarket Medical CEO Lee Maniscalco said: “The practical, clinical guidance these peer-reviewed publications offer to their readers and the wide variety of continuing education opportunities they provide throughout the year make this a perfect fit for Haymarket.” It's easy to see why Haymarket wants to play in the oncology space. The category was a rare bright spot in a bleak year for medical journals last year, with cancer therapies, the seventh-most heavily advertised area according to PERQ/HCI.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?